Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Triton acquires Bravida ASA
Mandate

Triton acquires Bravida ASA

February 19, 2007

Triton is acquiring roughly a total of 98 percent of the shares in Bravida ASA from Telenor ASA, Telenor Installation Holding AS, Sampo Life Insurance Company, Investment AB Latour, Stark II BV, Procuritas Capital Partners II LP, Procuritas Capital Partners IIB LP, SäkI AB and Baring European Fund (GP) LP. The Bravida group is the Nordic region's largest installation and service company with 8000 employees in Norway, Sweden and Denmark and sales of roughly SEK 9.5 billion. Bravida supplies solutions for the electricity, AC power, ventilation, security, service and property management industries, both the private and public sectors, and is represented in more that 150 locations in the Nordic region.

The legal advisor for Triton was the law firm of Vinge, with managing partner Christina Kokko handling mergers and acquisitions, and Mikael Ståhl for financing, who was assisted by Tom Zachrisson, Matti Scheffer, Peter Svanqvist, Johan Steen, Anna Elm and Kanja Berg.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026